Population Groups: Clinical Trials

55 trials of Population Groups, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 11 recruiting, 11 unknown, 7 not yet recruiting. 55 Phase 2, 5 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 255Completed 21, Recruiting 11, Unknown 11, Not yet recruiting 7, Withdrawn 2, Active not recruiting 1, Suspended 1, Terminated 1
Phase 15Recruiting 2, Active not recruiting 1, Completed 1, Unknown 1
Phase 35Completed 2, Not yet recruiting 1, Recruiting 1, Unknown 1

Follow Population Groups: new trials by email Literature Review of Population Groups trials Research Report on Population Groups

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg - Alzheimer Disease
Phase 2Not yet recruitingVigonvita Life Sciences2002026-11-012026-10-29
Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
reduced dose group, Standard Dose Group, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma (NPC)
Phase 2Not yet recruitingFudan University2692026-09-012026-08-27
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
VV119 2mg, VV119 4mg, VV119 6mg - Schizophrenia
Phase 2Not yet recruitingVigonvita Life Sciences5002026-07-312026-07-15
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group - Crohn's Disease
Phase 2Not yet recruitingJiangsu Carephar Pharmaceutical Co., Ltd.1562026-07-122026-06-30
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
low dose group, high dose group, Placebo group - Primary Immune Thrombocytopenia
Phase 2RecruitingHangzhou Sumgen Biotech Co., Ltd.602026-06-112026-09-09
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
JL18008 20 μg/kg, Placebo (for 20 μg/kg Group), JL18008 40 μg/kg - HIV Infections
Phase 1 / Phase 2RecruitingJecho Biopharmaceuticals Co., Ltd.302026-05-262026-08-06
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Placebo group, JS1-1-01 low-dose group, JS1-1-01 high-dose group - Depression
Phase 2 / Phase 3Not yet recruitingTasly Pharmaceutical Group Co., Ltd1802026-04-302026-04-08
Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)
Nafamostat Low-Dose Group, Nafamostat High-Dose Group - Continuous Renal Replacement Therapy (CRRT)
Phase 2RecruitingZhujiang Hospital922026-04-072026-11-18
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group) - Acute Ischemic Stroke
Phase 2RecruitingChangzhou Qianhong Bio-pharma Co., Ltd.3202026-01-192026-02-09
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group - ALS (Amyotrophic Lateral Sclerosis)
Phase 2 / Phase 3RecruitingShanghai Zhimeng Biopharma, Inc.2402025-10-302026-09-22
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
CM336 Injection(Low dose group), CM336 Injection(High dose group) - Primary Light-Chain Amyloidosis
Phase 2RecruitingKeymed Biosciences Co.Ltd902025-07-252025-11-26
Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
Lemborexant 5 mg, Control (placebo) group - Delirium - Postoperative, Cardiac Surgery
Phase 2Not yet recruitingUniversity of British Columbia602025-05-012025-04-23
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
LV232 40mg, LV232 60mg, Escitalopram - MDD
Phase 2RecruitingVigonvita Life Sciences4002025-04-032026-10-20
Evaluation of Postoperative Pain in Cases Undergoing Cataract Surgery Under Topical Versus General Anesthesia
Topical Anaesthesia group, General Anaesthesia group - Topical Anaesthesia, General Anesthetic Drug Adverse Reaction
Phase 1 / Phase 2Active not recruitingAlexandria University502025-04-022025-12-17
A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy
ET-26HCl 0.6mg/kg group, ET-26HCl 0.8mg/kg group, Etomidate Injectable Product 0.3mg/kg group - Gastroscopy, Colonoscopy
Phase 2CompletedAhon Pharmaceutical Co., Ltd.782024-11-152025-05-25
The Androtriol Injection for the Treatment of Acute Ischemic Stroke
Androtriol Injection (High-dose group), Androtriol Injection (Low-dose group), Hydroxypropyl-β-cyclodextrin injection - Acute Ischemic Stroke
Phase 2Not yet recruitingBeijing Tiantan Hospital3002024-10-312024-11-07
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group - Coronary Artery Disease
Phase 2RecruitingXijing Hospital182024-10-162026-01-23
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
SAL-0951 tablets 4mg, SAL-0951 tablets 5mg - Anemia
Phase 2RecruitingShenzhen Salubris Pharmaceuticals Co., Ltd.602024-09-142024-12-17
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg group - Focal Epilepsy
Phase 2RecruitingShanghai Zhimeng Biopharma, Inc.1802024-08-142026-09-22
A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Placebo group, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules - Depression
Phase 2CompletedTasly Pharmaceutical Group Co., Ltd2672023-12-262025-11-19

Showing 20 of 55. Sign in to see all of them.

Conditions studied

Ischemic Stroke (3)  ·  Alzheimer Disease (2)  ·  Cicatrix (2)  ·  Crohn Disease (2)  ·  Depression (2)  ·  Diabetic Nephropathies (2)  ·  Essential Hypertension (2)  ·  Heart Failure (2)  ·  Osteoarthritis, Knee (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Anemia (1)  ·  Anxiety, Separation (1)  ·  Arrhythmias, Cardiac (1)  ·  Breast Neoplasms (1)  ·  COVID-19 (1)

Sponsors

Tasly Pharmaceutical Group Co., Ltd (6)  ·  Vigonvita Life Sciences (3)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (2)  ·  Maternal and Child Health Hospital of Foshan (2)  ·  Shanghai Zhimeng Biopharma, Inc. (2)  ·  AIM Vaccine Co., Ltd. (1)  ·  Aalborg University Hospital (1)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Ahon Pharmaceutical Co., Ltd. (1)  ·  Alexandria University (1)  ·  Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1)  ·  Anterogen Co., Ltd. (1)  ·  Assiut University (1)  ·  Beijing Tiantan Hospital (1)  ·  Boryung Pharmaceutical Co., Ltd (1)

Countries

China (33)  ·  United States (4)  ·  South Korea (3)  ·  Egypt (2)  ·  Japan (2)  ·  Australia (1)  ·  Canada (1)  ·  Croatia (1)  ·  Denmark (1)  ·  Norway (1)  ·  Romania (1)  ·  Saudi Arabia (1)  ·  Taiwan (1)

Top investigators

Xiaoping Luo (2)  ·  Zhengping Liu, MD (2)  ·  Brian H. Kushner, MD (1)  ·  Byung-He Oh, Professor (1)  ·  Chao Gao, M.D., Ph.D. (1)  ·  Chunde Bao, M.D. & Ph.D. (1)  ·  DS Kim (1)  ·  Dae-Il Chang (1)  ·  Dong-Soo Kim, Professor (1)  ·  Fengcai Zhu (1)  ·  Gang An (1)  ·  Gi-Sik Kim, professor (1)  ·  Hesheng He (1)  ·  Hongmei Jing (1)

Results publications

PMID 11642645, PMID 15050897, PMID 16204011, PMID 17075123, PMID 2156418, PMID 22203761, PMID 22233247, PMID 22455987, PMID 22659077, PMID 23108976, PMID 23257654, PMID 23633099, PMID 23932463, PMID 24722445, PMID 25416198, PMID 26153128, PMID 26403468, PMID 27104183, PMID 27310019, PMID 27552452, PMID 27845852, PMID 28291178, PMID 28756065, PMID 29417902, PMID 29499740, PMID 30138014, PMID 3028661, PMID 3068365, PMID 30774462, PMID 31651889, PMID 32278352, PMID 32436160, PMID 32586366, PMID 33420185, PMID 33773111, PMID 3479839, PMID 35871083, PMID 36329428, PMID 38169574, PMID 39899673, PMID 42861767, PMID 9060524